Warner Bros. Discovery is trading flat on the week at $26.60, but the story worth watching is a persistent stream of insider selling from senior executives — including the CEO — against a backdrop where the Street's formal consensus remains nominally constructive.
The insider picture is one-directional and broad. CEO David Zaslav sold just over 200,000 shares on June 12 for roughly $5.5 million, the most recent in a string of executive disposals. Before that, the division CEO Jean-Briac Perrette sold 659,000 shares in March for $18 million, and an independent director sold 600,000 shares the same day for $16.4 million. Across the past 90 days, insider net selling totals nearly $47 million. Every trade in the recent record is a sale — there is no offsetting buying from any member of the executive team or board. The significance scores are modest, suggesting these are likely planned disposals rather than panic, but the uniformity of direction is hard to ignore when the stock is already 1.4% lower over the past month.
The borrow market has nothing meaningful to add to the bear case. Availability is effectively unconstrained — the lending pool holds over 2.4 billion shares available, dwarfing the 62 million shares currently short. Short interest is a low 2.5% of the free float, edging up slightly on the week after falling through late May and early June. Cost to borrow has eased to around 0.30%, down roughly 12% from a week ago. There is no squeeze pressure and no sign that short sellers are building an aggressive position. The ORTEX short score sits at 32.9 — middling territory — consistent with a stock where the short thesis is neither crowded nor fading fast. Options positioning has continued the drift toward less defensive territory noted in the previous note: the put/call ratio has slipped further to 1.94, now running about 1.6 standard deviations below its 20-day average of 2.06. That means the persistent put overhang of the past few months has continued to unwind, though a PCR near 2x still reflects meaningful hedging relative to most names.
The Street is formally buy-rated but the conviction is thin and the recent direction of travel was cautious. Two buys against one sell constitute the official consensus. The most recent action came in early May, when UBS lifted its target a dollar to $31 while holding at Neutral — a target that implies about 17% upside from current levels. Guggenheim reiterated Neutral the same day with no target update. Earlier in the quarter, Raymond James downgraded to Underperform and Benchmark dropped from Buy to Hold, both following the February earnings print. The analyst base, in aggregate, is clustering around $27-$31 targets — not far above where the stock trades today, which limits the return potential even from the more optimistic assumptions. The EV/EBITDA multiple is running around 11.6x, and has nudged lower over the past 30 days. The EPS yield is negative, reflecting continued net losses. On factor scores, EPS surprise ranks in the 99th percentile and 90-day EPS momentum is at the top of the universe — signalling the company has been beating estimates from a low bar — but forward EPS growth and near-term momentum scores are weak, sitting in the 17th and 8th percentiles respectively.
Institutional ownership gives a cleaner read on who is leaning in. BlackRock added roughly 2 million shares through May, bringing its stake to 7.8% of shares outstanding. Millennium Management added 18 million shares in Q1. Citadel and Balyasny both built meaningful new positions in the same period. These are active managers moving with conviction into a stock that passive money and index funds already hold in bulk — a mix that suggests at least some believe the current price is cheap relative to the restructuring optionality. On the other side, Sessa Capital trimmed 13.6 million shares in Q1, and the seller list at the institutional level is not empty. Peer context is mixed: ROKU and RBLX both jumped 14% on the week, while correlated names like SPHR were flat and CNVS surged 23% — suggesting the media and entertainment space had momentum this week that WBD did not fully capture.
Next earnings are scheduled for August 7. Between now and then, the most revealing data points will be whether the insider selling continues at pace as the stock hovers near the $26-$27 range where executives have been consistently willing to sell.
See the live data behind this article on ORTEX.
Open WBD on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
